Engrail Raises $32 Million From China Investors for CNS Drug Program
publication date: Aug 3, 2021
Engrail Therapeutics™, a San Diego neuroscience company, closed a $32 million extension of its Series A financing. With the $32 million, the total raised in the Series A is now $64 million, all of it from Nan Fung Life Sciences of Hong Kong. In addition, NFLS made a long-term commitment to invest $2 billion in the life science sector, which will enable Engrail to acquire assets with validated mechanisms for nervous system diseases. Engrail is open to licensing, co-development and acquisition deals. It acquires products while also developing candidates in-house. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.